Lineage Cell Therapeutics (LCTX) Net Cash Flow (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Net Cash Flow of -$4.8 million for Q1 2026, down 334.98% year-over-year from $2.1 million in Q1 2025, and down 3000.0% quarter-over-quarter from $167000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Net Cash Flow (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 334.98% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$12.3 million (down 385.55% YoY), while the FY2025 annual figure was -$5.4 million, down 151.89% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$4.8 million, down from $167000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $22.4 million in Q1 2022, with the low at -$45.4 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$1.8 million (2025), against an average of -$1.1 million.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 3695.32% in 2022, then jumped 385.8% in 2024.
- Lineage Cell Therapeutics' Net Cash Flow stood at -$13.3 million in 2022, then soared by 127.93% to $3.7 million in 2023, then surged by 385.8% to $18.0 million in 2024, then slumped by 99.07% to $167000.0 in 2025, then sank by 3000.0% to -$4.8 million in 2026.
- Business Quant data shows LCTX's Net Cash Flow at -$4.8 million in Q1 2026, $167000.0 in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | -4.84 Mn |
| Mar 31, 2026 | -4.84 Mn |
| Dec 31, 2025 | 167,000.00 |
| Dec 31, 2025 | 167,000.00 |
| Sep 30, 2025 | -1.79 Mn |
| Sep 30, 2025 | -1.79 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Jun 30, 2025 | -5.86 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Dec 31, 2024 | 18.02 Mn |
| Dec 31, 2024 | 18.02 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Jun 30, 2024 | -13.86 Mn |
| Jun 30, 2024 | -13.86 Mn |
| Mar 31, 2024 | 8.20 Mn |
| Mar 31, 2024 | 8.20 Mn |